目的 比較參松養(yǎng)心膠囊與比索洛爾治療腦心綜合征心律失常的臨床療效。方法 選擇哈勵(lì)遜國際和平醫(yī)院2013年3月-2017年5月腦心綜合征心律失?；颊?2例，隨機(jī)分為對照組和治療組，每組各46例。對照組在常規(guī)治療的基礎(chǔ)上口服富馬酸比索洛爾片，2.5 mg/次，1次/d。治療組在常規(guī)治療的基礎(chǔ)上口服參松養(yǎng)心膠囊，1.2 g/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效，同時(shí)比較治療前后兩組的心電圖療效、兒茶酚胺、血清丙二醛（MDA）、超氧化物歧化酶（SOD）水平變化和不良反應(yīng)情況。結(jié)果 治療后，對照組患者的總有效率為78.26%，顯著低于治療組的93.48%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對照組和治療組患者心電圖療效分別為56.52%、76.09%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組去甲腎上腺素（NE）、腎上腺素（E）和多巴胺（DA）水平較治療前均明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組兒茶酚胺水平均明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組血清MDA水平降低，SOD水平升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組MDA和SOD水平顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組的不良反應(yīng)發(fā)生率（6.52%）顯著低于對照組（21.73%），兩組比較差異具有統(tǒng)計(jì)學(xué)意義。結(jié)論 與比索洛爾相比，參松養(yǎng)心膠囊治療腦心綜合征心律失常的效果更優(yōu)，安全性更高，具有一定的臨床應(yīng)用價(jià)值。

Objective To compare the clinical effect between Shensong Yangxin Capsules and bisoprolol in treatment of cerebrocardiac syndrome with arrhythmia. Methods Patients (92 cases) with cerebrocardiac syndrome with arrhythmia in Harrison International Peace Hospital from March 2013 to May 2017 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Bisoprolol Fumarate Tablets on the basis of conventional therapy, 2.5 mg/time, once daily. Patients in the treatment group were po administered with Shensong Yangxin Capsules on the basis of conventional therapy, 1.2 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the ECG curative effect, catecholamine, malondialdehyde (MDA), superoxide dismutase (SOD) levels in serum, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 78.26%, which was significantly lower than 93.48% in the treatment group, and the difference was statistically significant between two groups (P<0.05). After treatment, the ECG curative effect in the control and treatment groups were 56.52% and 76.09%, respectively, and there were differences between two groups (P<0.05). After treatment, NE, E, and DA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the catecholamine level in the treatment group was significantly lower than those in the control group, with significant difference between two groups (P<0.05). MDA level in serum was decreased, but SOD level was increased, and the difference was statistically significant in the same group (P<0.05). And the MDA and SOD levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). The rate of adverse reactions in the treatment group was 6.52%, which was significantly lower than 21.73% in the control group, and the difference was statistically significant between two groups (P<0.05). Conclusion Compared with bisoprolol, Shensong Yangxin Capsules has better clinical effect in treatment of cerebrocardiac syndrome with arrhythmia with high safety, which has a certain clinical application value.

河北省醫(yī)學(xué)科學(xué)研究重點(diǎn)課題（2016326）